CNSP
CNS Pharmaceuticals Inc
NASDAQ: CNSP · HEALTHCARE · BIOTECHNOLOGY
$5.84
+1.57% today
Updated 2026-09-11
Market cap
$8.53M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-15.39
Dividend yield
—
52W range
$2 – $11
Volume
0.0M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.8
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-21.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$10.00
+71.23%
12-Month target
$5,277.00
+90259.59%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -21.12 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-3.54M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Net income | $-15.27M | $-18.85M | $-14.86M | $-15.85M | $-2.59M |
| EPS | — | — | — | — | $-15.39 |
| Free cash flow | $-10.56M | $-14.14M | $-17.12M | $-13.83M | $-3.54M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
CNS Pharmaceuticals Inc trades at $5.84. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -21.12, it sits in the distress.
Frequently asked questions
What is CNS Pharmaceuticals Inc's stock price?
CNS Pharmaceuticals Inc (CNSP) trades at $5.84.
Is CNS Pharmaceuticals Inc overvalued?
CNS Pharmaceuticals Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of CNS Pharmaceuticals Inc (CNSP)?
The 12-month analyst consensus target is $10.00, about 71.2% above the current $5.84. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
CNS Pharmaceuticals Inc's Altman Z-Score is -21.12, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-298.60%
Beta1.00
50D MA$5.44
200D MA$4.82
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—